Literature DB >> 29318507

Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?

Yoshikazu Ogawa1, Hidefumi Jokura2, Kuniyasu Niizuma3, Teiji Tominaga3.   

Abstract

Pituitary adenomas with high proliferation rate and rapid growth are well known, but the clinical characteristics, prognosis, and treatment algorithm remain unclear. The clinical characteristics and mid-term prognosis of patients with non-functioning pituitary adenomas with high proliferative potential were retrospectively investigated. This study identified 53 patients with Ki-67 labeling index of > 3% among 845 patients with non-functioning pituitary adenoma (6.3%) initially treated by surgery. Prophylactic treatment was not applied for patients with residual tumor, but salvage treatment was performed if tumor progression was identified within the follow-up period. Twenty-two patients remained progression-free, whereas 31 patients suffered tumor progression. Comparison of gross total removal (n = 22) and non-total removal (n = 31) groups showed significantly longer progression-free period in the former group (P < 0.001). As salvage treatment gamma knife radiosurgery was applied for 11 patients resulting in 10 patients remaining progression-free and regrowth in 1 patient. Fractionated irradiation was applied for 10 patients, resulting in 2 patients remaining progression-free, deaths in 5 patients including 3 of transformation to pituitary carcinoma, dementia in 1 patient caused by frontal lobe dysfunction, and progression in 2 patients requiring additional surgery and gamma knife radiosurgery. Temozolomide was administered in 2 patients, resulting in deaths in both patients including 1 transformation to pituitary carcinoma. Total removal and gamma knife radiosurgery can result in good outcome. However, the prognosis is extremely poor for patients inadequate for gamma knife radiosurgery. Development of new salvage treatments is essential.

Entities:  

Keywords:  Aggressive variant; Gamma knife; Ki-67 antigen; Non-functioning pituitary adenoma; Radiotherapy

Mesh:

Substances:

Year:  2018        PMID: 29318507     DOI: 10.1007/s11060-017-2740-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  36 in total

1.  A single centre's experience of stereotactic radiosurgery and radiotherapy for non-functioning pituitary adenomas with the Linear Accelerator (Linac).

Authors:  P J Wilson; K J De-Loyde; J R Williams; R I Smee
Journal:  J Clin Neurosci       Date:  2012-01-25       Impact factor: 1.961

2.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

3.  Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm.

Authors:  Luis V Syro; Humberto Uribe; Luis C Penagos; Leon D Ortiz; Camilo E Fadul; Eva Horvath; Kalman Kovacs
Journal:  Clin Endocrinol (Oxf)       Date:  2006-10       Impact factor: 3.478

Review 4.  Predictive markers of pituitary adenoma behavior.

Authors:  George Kontogeorgos
Journal:  Neuroendocrinology       Date:  2006-10-13       Impact factor: 4.914

Review 5.  Apoplexy of pituitary adenomas: the perfect storm.

Authors:  Edward H Oldfield; Marsha J Merrill
Journal:  J Neurosurg       Date:  2015-04-10       Impact factor: 5.115

6.  Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports.

Authors:  Yan Ji; Rachel Isaksson Vogel; Emil Lou
Journal:  Neurooncol Pract       Date:  2015-11-12

7.  A case of atypical thyrotroph cell adenoma, which re-grew within 3 months after surgery and required multimodal treatment.

Authors:  Yoshikazu Ogawa; Teiji Tominaga
Journal:  J Neurooncol       Date:  2007-11-07       Impact factor: 4.130

8.  MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry.

Authors:  S Trabelsi; N Mama; M Ladib; N Karmeni; M Haddaji Mastouri; M Chourabi; M Mokni; K Tlili; H Krifa; M T Yacoubi; A Saad; D H'mida Ben Brahim
Journal:  Clin Transl Oncol       Date:  2015-08-20       Impact factor: 3.405

Review 9.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Authors:  Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2007-02       Impact factor: 6.664

10.  p53 gene mutations in pituitary adenomas: rare events.

Authors:  A Levy; L Hall; W A Yeudall; S L Lightman
Journal:  Clin Endocrinol (Oxf)       Date:  1994-12       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.